Watch TOVX. Know when insiders buy.
One email the day a filing lands. Free.
TOVX
Theriva Biologics, Inc.
0.23
+0.00 +0.00%
USD · close Oct 1
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
43
WATCH · shorts 43
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $10.6MP/E 0.3DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$11.6MNET CASH $9.7M52W 0.18 – 0.84SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | — | — | −$3.3M | −$3.2M | — | -0.07 | −$3.1M | — | — | Aug 11 |
| Q1 2026 · Mar 31 | $300K | — | — | −$2.1M | −$2M | — | -0.05 | −$2.5M | — | — | Aug 11 |
| Q4 2025 · Dec 31derived | — | — | — | −$2.1M | −$2M | — | 1.30 | −$2.9M | $0 | −$2.9M | Mar 12 |
| Q3 2025 · Sep 30 | — | — | — | −$4.4M | −$4.4M | — | -0.45 | −$4.3M | $19K | −$4.3M | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$13.1M | −$13.1M | — | -1.93 | −$4.7M | — | — | Aug 11 |
| Q1 2025 · Mar 31 | — | — | — | −$4.4M | −$4.3M | — | -1.55 | −$4.8M | — | — | Aug 11 |
| Q4 2024 · Dec 31derived | — | — | — | −$4.6M | −$4.4M | — | 5.44 | −$4.7M | $0 | −$4.7M | Mar 12 |
| Q3 2024 · Sep 30 | — | — | — | −$7.9M | −$7.7M | — | -6.81 | −$3.9M | $0 | −$3.9M | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$8.5M | −$8.3M | — | -10.72 | −$3.5M | — | — | Nov 12 |
| Q1 2024 · Mar 31 | — | — | — | −$5.4M | −$5.2M | — | -7.53 | −$4.9M | — | — | Nov 12 |
| Q4 2023 · Dec 31derived | — | — | — | −$6.2M | −$5.5M | — | -8.10 | −$6.5M | $56K | −$6.6M | Mar 6 |
| Q3 2023 · Sep 30 | — | — | — | −$4.2M | −$3.3M | — | -4.85 | −$3M | $129K | −$3.1M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$24.1M | −$23.7M | — | -2.08 | −$16.7M | $35K | −$16.7M | — | — |
| FY2024 · to Dec 31 | — | — | −$26.3M | −$25.7M | — | -19.03 | −$16.9M | $1K | −$16.9M | — | — |
| FY2023 · to Dec 31 | — | — | −$21.4M | −$18.3M | — | -28.48 | −$19M | $202K | −$19.2M | — | — |
| FY2022 · to Dec 31 | — | — | −$21.6M | −$19.7M | — | -1.31 | −$19.1M | $116K | −$19.2M | — | — |
| FY2021 · to Dec 31 | — | — | −$14.3M | −$14.3M | — | -1.90 | −$12.9M | $14K | −$12.9M | — | — |
| FY2020 · to Dec 31 | — | — | −$10.2M | −$10M | — | -0.66 | −$12.2M | $9K | −$12.2M | — | — |
Every number comes from Theriva Biologics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.